ZUMA-1(NCT02348216)为一项单臂、多中心、注册性I/II期研究。ZUMA-1队列3是一项关于Axi-cel治疗R/R LBCL的安全性管理探索性研究,预防性使用托珠单抗和左乙拉西坦来控制毒性。队列3的R/R LBCL患者的主要纳入标准如下:组织学确诊为LBCL(包括弥漫大B细胞淋巴瘤[DLBCL]、原发纵隔大B细胞淋巴瘤[PMBCL]或转化型...
ZUMA-1(NCT02348216)为一项单臂、多中心、注册性I/II期研究。ZUMA-1队列3是一项关于Axi-cel治疗R/R LBCL的安全性管理探索性研究,预防性使用托珠单抗和左乙拉西坦来控制毒性。队列3的R/R LBCL患者的主要纳入标准如下:组织学确诊为LBCL(包括弥漫大B细胞淋巴瘤[DLBCL]、原发纵隔大B细胞淋巴瘤[PMBCL]或转化型...
该试验在ClinicalTrials.gov上注册，编号为#NCT02348216。
ClinicalTrials数据库提供临床试验Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC.的登记号NCT05620498,试验分期Phase 2以及申办者Tianjin Medical University Cancer Institute and Hosp
https://clinicaltrials.gov/ct2/show/NCT02684357 18. Rentz AM, Skalicky AM, Burslem K, et al. The content validity of the PSS in patients with plaque psoriasis. J Patient Rep Outcomes. 2017;1(1):4. doi:10.1186/s41687-017-0004-7PubMedGoogle ScholarCrossref 19. ...
Clinical trial information: NCT03088878.doi:10.1200/JCO.2021.39.15_suppl.7556Hun Ju LeeMichael Y. ChoiTanya SiddiqiJacqueline Claudia BarrientosWilliam G. WierdaIris IsufiJoseph M. TuscanoNicole LamannaSuki SubbiahJean Louise KoffAmerican Society of Clinical Oncology (ASCO)Journal of Clinical Oncology...
Navitoclax (oral BCL-XL/BCL-2 inhibitor) is being evaluated in a phase 2 study (REFINE, NCT03222609) in patients with myelofibrosis (MF). Historically, out... N Pemmaraju,TCP Somervaille,F Palandri,... - 《Clinical Lymphoma Myeloma & Leukemia》 被引量: 0发表: 2023年 Brentuximab vedotin ...
MSI-H/dMMR Solid Tumors Clinical Study Identifier NCT03736889 Sponsor BeiGene Last Modified on 26 May 2024 Contact a study center Get in touch with the nearest study center Select a site Send a message Entire World Results (11 sites found) Map ...
This study (NCT04191889) evaluated the benefit of combining camrelizumab and apatinib with HAIC-FOLFOX for HCC patients in BCLC stage C. Eligible patients were given a maximum of six cycles of HAIC-FOLFOX, along with camrelizumab and apatinib, until either disease progression or intolerable...
Idarucizumab has been evaluated in healthy male volunteers in a phase 1 randomized, placebo-controlled study (NCT0168830), which comprised 2 parts: a single risingdose evaluation of the safety, tolerability, and pharmacokinetics of idarucizumab alone (part 1) and a dose-finding, proof-of-conc...